When it comes to keenova announces unaudited fourth quarter 2025 financial results, keenova Therapeutics plc has announced its unaudited financial results for the fourth quarter ending December 31, 2025, showcasing a significant increase in net sales and a promising outlook for 2026. The company reported net sales of $543.0 million for the quarter, a remarkable rise of $277.3 million compared to the same period last year. This growth is primarily attributed to the strong performance of Acthar® Gel and the inclusion of XIAFLEX® in their portfolio.
Acthar Gel generated net sales of $205.6 million, reflecting a 48% increase driven by heightened demand and effective marketing strategies that bolstered its market share. Similarly, XIAFLEX contributed $156.5 million to the company's revenue, underscoring the successful transition Keenova has made into a branded therapeutics company. Learn more on Investopedia.
Understanding Keenova Announces Unaudited Fourth Quarter 2025 Financial Results
Keenova's financial and operational performance for the fourth quarter of 2025 surpassed initial expectations as the company completed its transition towards focusing primarily on branded therapeutics. Despite reporting a loss from continuing operations projected between $105.0 million and $115.0 million for the quarter, this is a stark contrast to the income of $566.4 million reported during the same quarter in 2024. The shift can be largely attributed to costs associated with recent mergers and transactions, including the Mallinckrodt-Endo merger and subsequent Par Health spin-off.
In a more positive light, Adjusted EBITDA from continuing operations is anticipated to be in the range of $210.0 million to $220.0 million, bolstered by the increased sales from Acthar Gel and XIAFLEX, along with the realization of initial merger-related synergies. Keenova reported $13 million in pre-tax merger synergies during the fourth quarter, with expectations to reach about $100 million in 2026 as the company aims for $150 million in annual pre-tax, run-rate synergies by the anniversary of the merger.
Hammer Toe Trial Shows Promising Results
In addition to financial highlights, Keenova announced the successful outcomes of its Hammer Toe trial, which met both its primary safety endpoint and secondary, exploratory efficacy endpoints. This is a significant advancement for Keenova as it continues to expand its portfolio with innovative treatments. The positive results from the trial bolster the company's commitment to enhancing its therapeutic offerings and adDressing unmet medical needs.
The outcomes of the trial not only reinforce Keenova's operational capabilities but also establish a solid foundation for future growth, as they explore additional opportunities within their therapeutic areas. The company's focus on research and development will be crucial in sustaining momentum and expanding their product offerings.
Guidance for 2026 Highlights Growth Prospects
Looking ahead, Keenova has provided its financial guidance for the full year of 2026, projecting net sales between $1.94 billion and $2.00 billion, along with an Adjusted EBITDA guidance of $730 million to $760 million. These forecasts reflect a robust growth trajectory, incorporating the anticipated synergies from the recent merger. The company's capital allocation priorities for the coming year include investing in organic growth to enhance commercial execution for Acthar Gel and XIAFLEX, as well as targeted research and development initiatives.
Moreover, Keenova is exploring potential acquisitions that could leverage their existing capabilities to further enhance growth. There are also discussions surrounding opportunistic divestitures, including a possible sale of the PERCOCET® business, as the company aligns its portfolio to maximize its market position.
As Keenova navigates the complexities of the pharmaceutical landscape, the company remains committed to delivering value to its shareholders while driving innovation in the therapeutic space. With a solid financial foundation and a clear strategic vision, Keenova is poised to make significant strides in 2026 and beyond.
Originally reported by Benzinga. View original.